Hepatitis C Virus and Innate Interferon Response: Pathogen Biology, Drug Resistance, Novel Drug Targets, and Therapeutic Strategies

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Pathogenicity and Drug Resistance of Human Pathogens

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-981-32-9449-3_12
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.

  2018cited by this paper
• Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

  2018cited by this paper
• Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

  2018cited by this paper
• Era of direct acting anti-viral agents for the treatment of hepatitis C

  2018cited by this paper
• Ombitasvir-Paritaprevir-Ritonavir-Dasabuvir (Viekira Pak)–Induced Lactic Acidosis

  2017cited by this paper
• Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.

  2017cited by this paper
• Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways.

  2017cited by this paper
• In vitro Selection of Resistance to Sofosbuvir in HCV Replicons of Genotype-1 to -6

  2017cited by this paper
• High antiviral activity of NS5A inhibitor ABT‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection

  2016cited by this paper
• Hepatitis C Virus and Antiviral Drug Resistance

  2016cited by this paper
• Direct anti-HCV agents

  2015cited by this paper
• Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

  2015cited by this paper
• Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness

  2015cited by this paper
• Hepatitis C virus drug resistance–associated substitutions: State of the art summary

  2015cited by this paper
• Pathogen-Associated Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is Dependent on U-Core Length

  2015cited by this paper
• Activation and evasion of antiviral innate immunity by hepatitis C virus.

  2014cited by this paper
• Hepatitis C virus NS4B protein targets STING and abrogates RIG‐I–mediated type I interferon‐dependent innate immunity

  2013cited by this paper
• Ultrastructural analysis of hepatitis C virus particles

  2013cited by this paper
• Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity.

  2013cited by this paper
• Hepatitis C virus proteins: from structure to function.

  2013cited by this paper
• Class A Scavenger Receptor 1 (MSR1) Restricts Hepatitis C Virus Replication by Mediating Toll-like Receptor 3 Recognition of Viral RNAs Produced in Neighboring Cells

  2013cited by this paper
• Innate immune responses in hepatitis C virus infection

  2012cited by this paper
• Extensive evolutionary and functional diversity among mammalian AIM2-like receptors

  2012cited by this paper
• Sensing of RNA Viruses: a Review of Innate Immune Receptors Involved in Recognizing RNA Virus Invasion

  2012cited by this paper
• The mitochondrial targeting chaperone 14-3-3ε regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity.

  2012cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• Toll-Like Receptor Signaling in Liver Diseases

  2011cited by this paper
• Immune signaling by RIG-I-like receptors.

  2011cited by this paper
• Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition

  2011cited by this paper
• A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Analysis of Interferon Signaling by Infectious Hepatitis C Virus Clones with Substitutions of Core Amino Acids 70 and 91

  2011cited by this paper
• Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

  2011cited by this paper
• IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones.

  2010cited by this paper
• Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

  2010cited by this paper
• Factors to Improve the Management of Hepatitis C in Drug Users: An Observational Study in an Addiction Centre

  2010cited by this paper
• ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization

  2009cited by this paper
• STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity

  2009cited by this paper
• Solution Structures of Cytosolic RNA Sensor MDA5 and LGP2 C-terminal Domains

  2009cited by this paper
• The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.

  2009cited by this paper
• Association Between Hepatitis C and Hepatocellular Carcinoma

  2009cited by this paper
• Differential recognition of double-stranded RNA by RIG-I–like receptors in antiviral immunity

  2008cited by this paper
• Interferon signaling and treatment outcome in chronic hepatitis C

  2008cited by this paper
• Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma

  2007cited by this paper
• Hepatitis C Virus Nonstructural Protein 5A Modulates the Toll-Like Receptor-MyD88-Dependent Signaling Pathway in Macrophage Cell Lines

  2007cited by this paper
• Hepatitis C virus non-structural protein-2 activates CXCL-8 transcription through NF-κB

  2007cited by this paper
• Function of RIG-I-like Receptors in Antiviral Innate Immunity*

  2007cited by this paper
• Regulation of innate immunity against hepatitis C virus infection

  2007cited by this paper
• Interferons at age 50: past, current and future impact on biomedicine

  2007cited by this paper
• 5'-Triphosphate RNA Is the Ligand for RIG-I

  2006cited by this paper
• Innate immune recognition of viral infection

  2006cited by this paper
• RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-Phosphates

  2006cited by this paper
• Pathogen recognition and innate immunity.

  2006cited by this paper
• The dsRNA binding site of human Toll‐like receptor 3

  2006cited by this paper
• Type I interferons in host defense.

  2006cited by this paper
• Viral hepatitis in India.

  2006cited by this paper
• Stealth and Cunning: Hepatitis B and Hepatitis C Viruses

  2005cited by this paper
• Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8

  2004cited by this paper
• Hepatitis C virus NS5A: tales of a promiscuous protein.

  2004cited by this paper
• The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

  2004cited by this paper
• Genetic diversity and evolution of hepatitis C virus--15 years on.

  2004cited by this paper
• Toll-like receptor signalling

  2004cited by this paper
• The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway

  2003cited by this paper
• Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA.

  2003cited by this paper
• Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection

  2001cited by this paper
• Signal Integration via PKR

  2001cited by this paper
• The interleukin‐1 receptor/Toll‐like receptor superfamily: signal generators for pro‐inflammatory interleukins and microbial products

  2000cited by this paper
• Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.

  1999cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways.

  1998cited by this paper

• No citing papers are available for this paper.